Company / SG&A Expense
CRESCENT BIOPHARMA, INC. SG&A Expense History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$25.4M
FY2025
5-year range
$2.2M / $25.4M
FY2021-FY2025
Trend
+225.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense changed +225% YoY in FY2025, a notable deviation from the 4-year average annual change of +101%.
Based on SEC 10-K filings.
$25M in FY2025 with a 10-year CAGR of +24.2%.
Increased from $7M to $25M over the past 9 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +24.2%
Key checks
Key Insights
- CRESCENT BIOPHARMA, INC.'s sg&a expense has grown for 4 consecutive years.
- In FY2025, sg&a expense increased 225.3% year-over-year.
- Lowest sg&a expense in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.4M | +225.3% |
| FY2017 | $7.8M | +18.3% |
| FY2016 | $6.6M | +127.6% |
| FY2015 | $2.9M | +32.7% |
| FY2014 | $2.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026